IL6 and androgen insensitivity syndrome: The study attempted to demonstrate that IL-6 could serve as a reliable prognostic factor in the acute phase of AIS, as well as a biomarker for the development of clinical complications resulting from acute ischemia, or to assess the severity of neurological deficits and the prognosis of patients after AIS.